blood cell News
-
HORIBA acquired 10,000m2 site for new reagent plant in Brazil
Production capacity of hematology reagents is to be doubled Handle expansion in medical services driven by economic growth HORIBA Group's local subsidiary in Brazil, HORIBA ABX Ltda. (1), acquired a 10,000 m2 site(2) on the outskirts of Sao Paolo, Brazil, and will construct a plant there for the manufacture of hematology reagents(3) for hospitals where hematology analyzers are used. The intent ...
-
New China plant fully completed
Production of reagents for hematology analyzer to be newly undertaken Existing plants to be consolidated into this core plant Begun in April of last year, construction of our new plant in Shanghai, China has been now been fully completed. The new plant comprises two buildings. The Phase 1 building was completed in August of last year, after which certain production operations were shifted from ...
-
Blood & Stem Cell Donation From Astim
As Astim Family with all our employees, we have become donors for society and life. Turkish Red Crescent, which serves with 67 blood donation centers and mobile blood donation vehicles, with the purpose of meeting whole blood demand from continuous volunteers, was the guest of Astim. In the Red Crescent mobile blood donation vehicle that visited our company, 50% of our total staff that was found ...
By ASTIM A.S.
-
Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as ...
-
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
-
SQZ Biotechnologies Announces Integrated Point-ofCare Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ) announced today that the company’s rst generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specications relative to current clean room-based processes used in clinical development. The non-clinical studies showed that the ...
-
Part of the Cell and Gene Therapy Catapult PAT Consortium
Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve ...
-
Bilix, containing the identity of reverse thinking and novelty
1 Establishment of new drug pipeline with bilirubin platform technology Securing global competitiveness by increasing corporate value “I want to give hope to those who are living a difficult life with an incurable disease” [IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, ...
-
New Study Establishes Cytovale IntelliSep Test in the Rapid Diagnosis of Sepsis
Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal PLOS ONE evaluating its IntelliSep test in the rapid diagnosis of sepsis in the hospital emergency department. Data from the study, “Development and validation of a cellular ...
-
GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences
GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company's advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the ...
-
New Study Supports Cytovale IntelliSep Test as Promising Tool to Aid in the Rapid Diagnosis of Sepsis in the Emergency Department
Cytovale, a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal Critical Care Explorations (CCE) evaluating its IntelliSep test as a tool in the rapid diagnosis of sepsis in the hospital emergency department (ED). Data from the study, ...
-
Alfa Chemistry—Reliable Supplier of Custom Synthesis of Functional Polymers
While providing various types of functional polymers that are readily available, Alfa Chemistry’s management also fully understands that there is a vast demand for tailor-made polymers. Therefore, the company recently announces its ability for custom synthesis of various functional polymers. For researchers or manufacturers who are seeking for functional polymers of special type or size ...
-
X-ZELL hMX technology now available for research use
X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the company’s single-cell diagnostics platform, which is capable of isolating and visualising individual atypical cells from a small 10mL blood sample. According to X-ZELL’s Head of Engineering ...
By X-Zell Inc.
-
MOU for Joint Development of AntiCancer Drugs with Frontbio and Daewoong Bio
MOU for Joint Development of Anti-Cancer Drugs with FRONTBIO and DAEWOONG BIO On the 21st, FRONTBIO, a new drug development bio company, announced that it had signed an MOU for the joint development of anticancer drugs with DAEWOONG BIO, a company specializing in the production and development of the best raw materials and finished drugs in Korea. By combining FRONTBIO's anticancer drug ...
By Frontbio
-
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024. The company previously ...
By MorphoSys AG
-
Sysmex Continues to Evolve Its Hematology Product Portfolio
Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer (“XN-Series”) in 2011, combining modules for blood count, smear ...
-
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June ...
-
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome ...
-
Creative Enzymes Offers the Raw Materials for Sialic Acid Assay Kit Manufacture
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained a solid reputation. Recently, Creative Enzymes announced the raw ...
-
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the executive management team will present and host meetings with investors at the virtual Guggenheim ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you